Abstract
AbstractIn coronavirus disease 2019 (Covid-19) era, neuroinflammation may develop due to neuronal tropism of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and/or associated immune activation, cytokine storm, and psychological stress. SARS-CoV-2 infection and linked cytokine storm may cause blood–brain barrier (BBB) injury through which activated immune cells and SARS-CoV-2 can pass into the brain causing activation of glial cells with subsequent neuroinflammation. Different therapeutic regimens were suggested to alleviate Covid-19-induced neuroinflammation. Since glibenclamide has anti-inflammatory and neuroprotective effects, it could be effective in mitigation of SARS-CoV-2 infection-induced neuroinflammation. Glibenclamide is a second-generation drug from the sulfonylurea family, which acts by inhibiting the adenosine triphosphate (ATP)-sensitive K channel in the regulatory subunit of type 1 sulfonylurea receptor (SUR-1) in pancreatic β cells. Glibenclamide reduces neuroinflammation and associated BBB injury by inhibiting the nod-like receptor pyrin 3 (NLRP3) inflammasome, oxidative stress, and microglial activation. Therefore, glibenclamide through inhibition of NLRP3 inflammasome, microglial activation, and oxidative stress may attenuate SARS-CoV-2-mediated neuroinflammation.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Immunology
Reference65 articles.
1. Abdallah DM, Nassar NN, Abd-El-Salam RM (2011) Glibenclamide ameliorates ischemia–reperfusion injury via modulating oxidative stress and inflammatory mediators in the rat hippocampus. Brain Res 1385:257–262
2. Abubakar MB, Usman D, El-Saber Batiha G, Cruz-Martins N, Malami I, Ibrahim KG, Abubakar B, Bello MB, Muhammad A, Gan SH, Dabai AI, Alblihed M, Ghosh A, Badr RH, Thangadurai D, Imam MU (2021) Natural products modulating angiotensin converting enzyme 2 (ACE2) as potential COVID-19 therapies. Front Pharmacol 12:629935. https://doi.org/10.3389/fphar.2021.629935 (PMID:34012391;PMCID:PMC8126690)
3. Al-kuraishy H, Al-Gareeb AI, Abdullah SM, Cruz-Martins N, Batiha GES (2021a) Response: commentary: case report: hyperbilirubinemia in gilbert syndrome attenuates covid-19-induced metabolic disturbances. Front Cardiovasc Med. 8:1264
4. Al-kuraishy H, Al-Gareeb AI, Guerreiro SG, Cruz-Martins N, Batiha GE (2021b) COVID-19 in relation to hyperglycemia and diabetes mellitus. Front Cardiovasc Med 8:335
5. Al-Kuraishy HM, Al-Gareeb AI, Alkazmi L, Habotta OA, Batiha GE (2022a) High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons. Inflammopharmacology 30:811–820. https://doi.org/10.1007/s10787-022-00988-y
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献